Inovio Pharmaceuticals (INO) Stock Forecast & Price Target

Inovio Pharmaceuticals is viewed positively because VOCERYQ’s accelerated FDA approval makes INO-3107 the company’s first FDA-approved product and the first FDA-approved DNA medicine, validating its proprietary CELLECTRA-based platform and opening a real commercial path in RRP. The approval could support meaningful economics, with peak annual sales estimated at $450M, while the differentiated surgical-burden reduction profile in a chronic, rare disease addresses clear unmet need despite competitive pressure. Additional upside comes from partner-driven VGX-3100 Phase 3 positive data in China, potential up to $20M in milestone payments plus royalties, and earlier 2026 collaboration progress in GBM and next-generation DNA medicine programs.

Inovio Pharmaceuticals is a clinical-stage biotechnology company with a limited revenue base and persistent cash burn, as shown by a 1Q26 net loss of $19.7M, or ($0.28) per share, and operating cash outflows of $21.6M. Its pro forma cash balance of $53.7M after the April 2026 public offering may fund operations only into 1Q27, supporting the view that additional financing is likely needed within the next 12 months and that dilution risk remains meaningful. Fundamentally, the investment case depends heavily on INO-3107, but clinical, regulatory, and commercial uncertainty around recurrent respiratory papillomatosis, combined with the company’s negative operating profile, makes the outlook cautious.